Asparaginase Escherichia coli
- Generic Name
- Asparaginase Escherichia coli
- Brand Names
- Rylaze, Spectrila
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9015-68-3
- Unique Ingredient Identifier
- G4FQ3CKY5R
- Background
Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exhibit antitumor actions in models of leukaemias . L-asparaginase of E. coli is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from E. coli works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death . For patients who develop hypersensitivity to E. coli-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated Asparaginase Erwinia chrysanthemi is recommended .
- Indication
Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 59
- Registration Number
- NCT00003671
- Locations
- 🇺🇸
Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
🇺🇸West Virginia University Hospitals, Morgantown, West Virginia, United States
🇺🇸Madigan Army Medical Center, Tacoma, Washington, United States
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: mercaptopurineDrug: methotrexateDrug: pegaspargaseDrug: prednisoneDrug: therapeutic hydrocortisoneDrug: thioguanineDrug: vincristine sulfateRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-09-01
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1970
- Registration Number
- NCT00002744
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸Children's Hospital and Medical Center - Seattle, Seattle, Washington, United States
Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
- Conditions
- LeukemiaLymphoma
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002471
- Locations
- 🇺🇸
Kaplan Cancer Center, New York, New York, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
- Registration Number
- NCT00002499
- Locations
- 🇦🇷
Grupo Argentino de Tratamiento de la Leucemia Aguda, Buenos Aires, Argentina
SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia
- Conditions
- LeukemiaNeutropeniaThrombocytopenia
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 50
- Registration Number
- NCT00002665
- Locations
- 🇺🇸
CCOP - Dayton, Kettering, Ohio, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002691
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: filgrastimDrug: asparaginaseDrug: cyclophosphamideDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: etoposideDrug: leucovorin calciumDrug: liposomal cytarabineDrug: mercaptopurineDrug: mesnaDrug: methotrexateDrug: therapeutic hydrocortisoneDrug: thiotepaDrug: vincristine sulfateRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 156
- Registration Number
- NCT00002704
- Locations
- 🇺🇸
West Virginia University Hospitals, Morgantown, West Virginia, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Registration Number
- NCT00002785
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- United Kingdom Children's Cancer Study Group
- Target Recruit Count
- 100
- Registration Number
- NCT00003423
- Locations
- 🇬🇧
Hospital for Sick Children NHS Trust, London, England, United Kingdom
Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: filgrastimDrug: asparaginaseDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: melphalanDrug: thioguanineProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 35
- Registration Number
- NCT00004056
- Locations
- 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.